140 related articles for article (PubMed ID: 20847447)
1. Regulation of in vitro Aβ1-40 aggregation mediated by small molecules.
Kim HY; Kim Y; Han G; Kim DJ
J Alzheimers Dis; 2010; 22(1):73-85. PubMed ID: 20847447
[TBL] [Abstract][Full Text] [Related]
2. Docosahexaenoic acid disrupts in vitro amyloid beta(1-40) fibrillation and concomitantly inhibits amyloid levels in cerebral cortex of Alzheimer's disease model rats.
Hashimoto M; Shahdat HM; Yamashita S; Katakura M; Tanabe Y; Fujiwara H; Gamoh S; Miyazawa T; Arai H; Shimada T; Shido O
J Neurochem; 2008 Dec; 107(6):1634-46. PubMed ID: 19014387
[TBL] [Abstract][Full Text] [Related]
3. The synaptic protein neuroligin-1 interacts with the amyloid β-peptide. Is there a role in Alzheimer's disease?
Dinamarca MC; Weinstein D; Monasterio O; Inestrosa NC
Biochemistry; 2011 Sep; 50(38):8127-37. PubMed ID: 21838267
[TBL] [Abstract][Full Text] [Related]
4. Development of a proteolytically stable retro-inverso peptide inhibitor of beta-amyloid oligomerization as a potential novel treatment for Alzheimer's disease.
Taylor M; Moore S; Mayes J; Parkin E; Beeg M; Canovi M; Gobbi M; Mann DM; Allsop D
Biochemistry; 2010 Apr; 49(15):3261-72. PubMed ID: 20230062
[TBL] [Abstract][Full Text] [Related]
5. Genetically augmenting tau levels does not modulate the onset or progression of Abeta pathology in transgenic mice.
Oddo S; Caccamo A; Cheng D; Jouleh B; Torp R; LaFerla FM
J Neurochem; 2007 Aug; 102(4):1053-63. PubMed ID: 17472708
[TBL] [Abstract][Full Text] [Related]
6. The recombinant amyloid-beta peptide Abeta1-42 aggregates faster and is more neurotoxic than synthetic Abeta1-42.
Finder VH; Vodopivec I; Nitsch RM; Glockshuber R
J Mol Biol; 2010 Feb; 396(1):9-18. PubMed ID: 20026079
[TBL] [Abstract][Full Text] [Related]
7. Amyloid-beta aggregation.
Finder VH; Glockshuber R
Neurodegener Dis; 2007; 4(1):13-27. PubMed ID: 17429215
[TBL] [Abstract][Full Text] [Related]
8. A strategy for designing a peptide probe for detection of β-amyloid oligomers.
Hu Y; Su B; Kim CS; Hernandez M; Rostagno A; Ghiso J; Kim JR
Chembiochem; 2010 Nov; 11(17):2409-18. PubMed ID: 21031399
[TBL] [Abstract][Full Text] [Related]
9. Structure inducing ionic liquids-enhancement of alpha helicity in the Abeta(1-40) peptide from Alzheimer's disease.
Debeljuh N; Barrow CJ; Henderson L; Byrne N
Chem Commun (Camb); 2011 Jun; 47(22):6371-3. PubMed ID: 21547327
[TBL] [Abstract][Full Text] [Related]
10. High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain.
Güntert A; Döbeli H; Bohrmann B
Neuroscience; 2006 Dec; 143(2):461-75. PubMed ID: 17008022
[TBL] [Abstract][Full Text] [Related]
11. Abeta-globulomers are formed independently of the fibril pathway.
Gellermann GP; Byrnes H; Striebinger A; Ullrich K; Mueller R; Hillen H; Barghorn S
Neurobiol Dis; 2008 May; 30(2):212-20. PubMed ID: 18353662
[TBL] [Abstract][Full Text] [Related]
12. The Osaka FAD mutation E22Δ leads to the formation of a previously unknown type of amyloid β fibrils and modulates Aβ neurotoxicity.
Ovchinnikova OY; Finder VH; Vodopivec I; Nitsch RM; Glockshuber R
J Mol Biol; 2011 May; 408(4):780-91. PubMed ID: 21402079
[TBL] [Abstract][Full Text] [Related]
13. Low-n oligomers as therapeutic targets of Alzheimer's disease.
Ono K; Yamada M
J Neurochem; 2011 Apr; 117(1):19-28. PubMed ID: 21244429
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and evaluation of ferrocenoyl pentapeptide (Fc-KLVFF) as an inhibitor of Alzheimer's Aβ₁-₄₂ fibril formation in vitro.
Wei CW; Peng Y; Zhang L; Huang Q; Cheng M; Liu YN; Li J
Bioorg Med Chem Lett; 2011 Oct; 21(19):5818-21. PubMed ID: 21855336
[TBL] [Abstract][Full Text] [Related]
15. Peptide and protein mimetics inhibiting amyloid beta-peptide aggregation.
Takahashi T; Mihara H
Acc Chem Res; 2008 Oct; 41(10):1309-18. PubMed ID: 18937396
[TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal fluid amyloid beta peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: indication of carrier-mediated epitope masking of amyloid beta peptides.
Bibl M; Esselmann H; Otto M; Lewczuk P; Cepek L; Rüther E; Kornhuber J; Wiltfang J
Electrophoresis; 2004 Sep; 25(17):2912-8. PubMed ID: 15349929
[TBL] [Abstract][Full Text] [Related]
17. Identification and characterization of key kinetic intermediates in amyloid beta-protein fibrillogenesis.
Kirkitadze MD; Condron MM; Teplow DB
J Mol Biol; 2001 Oct; 312(5):1103-19. PubMed ID: 11580253
[TBL] [Abstract][Full Text] [Related]
18. Development of retro-inverso peptides as anti-aggregation drugs for β-amyloid in Alzheimer's disease.
Matharu B; El-Agnaf O; Razvi A; Austen BM
Peptides; 2010 Oct; 31(10):1866-72. PubMed ID: 20633587
[TBL] [Abstract][Full Text] [Related]
19. Efficient reversal of Alzheimer's disease fibril formation and elimination of neurotoxicity by a small molecule.
Blanchard BJ; Chen A; Rozeboom LM; Stafford KA; Weigele P; Ingram VM
Proc Natl Acad Sci U S A; 2004 Oct; 101(40):14326-32. PubMed ID: 15388848
[TBL] [Abstract][Full Text] [Related]
20. Probing and trapping a sensitive conformation: amyloid-β fibrils, oligomers, and dimers.
Fawver JN; Duong KT; Wise-Scira O; Petrofes Chapa R; Schall HE; Coskuner O; Zhu X; Colom LV; Murray IV
J Alzheimers Dis; 2012; 32(1):197-215. PubMed ID: 22785403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
